The vaccine developed against colorectal (rectal and colon) cancer, as well as malignant tumors in the pancreas, has successfully passed the first trials on humans. According to reports, immune response was observed in 84% of patients Memorial Sloan Kettering Cancer Center (MSKCC).
The first phase of the vaccine’s clinical trials included 25 patients with malignant tumors of the pancreas or intestine who had KRAS mutations and were at high risk of recurrence after surgery. The results showed that the vaccine was safe and stimulated the immune system to produce cancer-fighting cells.
Immune response was observed in 84% of patients. This means that immune T cells targeting the tumor with the KRAS mutation are more active and more numerous. They also increased their life expectancy without cancer recurrence. The amount of tumor DNA in the blood decreased in 84% of the patients, and there was no tumor DNA in 24%.
The vaccine was injected into four sites, one in each arm and leg. It caused mild side effects such as pain and fatigue, but was better tolerated than standard chemotherapy or radiation therapy. The second phase of clinical trials started in December 2023. In addition to the vaccine under study, other types of vaccines against pancreatic and colorectal cancer are being developed.
“This gives hope to people with pancreatic and colorectal cancer who have not received effective treatment for recurrent disease,” the oncologists said.
Previous scientists to create An effective way to prevent pancreatitis after endoscopy.